OR WAIT null SECS
March 06, 2025
In an interview with Pharmaceutical Technology®, Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
February 28, 2025
Treatments for autoimmune diseases, multiple cancers, and skin blistering have been recommended for marketing approval.
February 17, 2025
The agency has received certification with the Eco-Management and Audit Scheme for its commitment to environmental sustainability.
February 03, 2025
EMA introduced its New Fee Regulation in January 2025, but what impact will the new fees and charges have on medicine developers?
January 29, 2025
The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.
January 23, 2025
The agency’s newly issued letter to Sanofi amends one sent in December 2024, and stems from inspections at its Massachusetts drug manufacturing facility in June and July 2024.
January 17, 2025
Pharmaceutical Technology® spoke with Charles Ruban, president and CEO, Verdot, about the focus of moving to sustainability practices in pharmaceutical manufacturing.
January 10, 2025
The HTAR, which aims to increase access to new medicines, becomes effective Jan. 12, 2025.
Patrizia Cavazzoni, director of FDA’s Center for Drug Evaluation and Research, has announced her retirement from the agency.
January 06, 2025
Pharmaceutical Technology chats about continuous processes and regulatory considerations for processing equipment with Christian Dunne from ChargePoint Technology.